COMBINE

Collaboration for prevention and treatment of MDR bacterial infections

Summary

IMI’s Antimicrobial Resistance (AMR) Accelerator programme comprises several projects with the shared goal of progressing the development of new medicines to treat or even prevent resistant bacterial infections in Europe and worldwide. The COMBINE project was created to coordinate the AMR Accelerator projects and provide them with the resources they need to achieve their goals.

These include data management guidelines and an IT infrastructure to enable the collection, aggregation, storage, sharing and analysis of datasets generated by AMR Accelerator projects. COMBINE will also help to ensure that data adheres to ‘FAIR’ principles, i.e. it is findable, accessible, interoperable, and re-useable. Promoting communication among the projects is another COMBINE priority.

On the scientific front, COMBINE aims to improve the animal models used in AMR research and develop improved tools to reliably translate results in animals into results in humans. The project also aims to optimise the design and analysis of clinical trials. These tools will help all projects in the programme to deliver results that will help to accelerate the development of novel antibiotics and vaccines against AMR.

Participants

  Show participants on map
EFPIA companies
  • Evotec International GMBH, Hamburg, Germany
  • Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
  • Janssen Pharmaceutica Nv, Beerse, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Beam Alliance, Paris, France
  • Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel, Langen, Germany
  • Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung Ev, München, Germany
  • Statens Serum Institut, Copenhagen S, Denmark
  • Uppsala Universitet, Uppsala, Sweden
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Asclepia Outsourcing Solutions, Destelbergen, Belgium
  • Biocom AG, Berlin, Germany
  • Gritsystems As, Dragør, Denmark

Participants
NameIHI funding in €
Asclepia Outsourcing Solutions461 250
Beam Alliance104 255
Biocom AG618 750
Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel1 466 860
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung Ev800 000
Gritsystems As800 625
Statens Serum Institut685 000
Uppsala Universitet3 063 260
Total Cost8 000 000